People: Cardiome Pharma Corp. (CRME.O)

CRME.O on Consolidated Issue listed on NASDAQ Global Market

5.19USD
9 Feb 2010
Price Change (% chg)

$0.12 (+2.37%)
Prev Close
$5.19
Open
--
Day's High
$5.29
Day's Low
$5.14
Volume
112,848
Avg. Vol
172,408
52-wk High
$5.88
52-wk Low
$2.57

view people for:

Summary

Name Age Since Current Position
Rieder, Robert 63 2009 Executive Chairman of the Board
Janzen, Douglas 40 2009 President, Chief Executive Officer, Director
Sikorsky, Curtis 2006 Chief Financial Officer
Lalji, Karim 2007 Senior Vice President - Commercial Affairs
Grant, Sheila 2005 Vice President - Product Development, Vernakalant
Boivin, Taryn 2005 Vice President - Pharmaceutical Sciences & Manufacturing
McAfee, Donald 2007 Chief Scientific Officer
Glickman, Richard 2007 Lead Independent Director
Shlevin, Harold 2004 Director
Clegg, Jackie 47 2004 Director
Roberts, Peter 2005 Director
Hunter, William 46 2007 Director
» Insider Trading

Biographies

Name Description
Rieder, Robert Mr. Robert W. Rieder, M.B.A. serves as Executive Chairman of the Board and resigned as Chief Executive Officer of Cardiome Pharma Corp. effective August 4, 2009. He had also previously served as Cardiome’s Vice-Chairman. He joined Cardiome in April 1998 as President and Chief Executive Officer. Mr. Rieder has extensive experience in venture capital and in operational management. Prior to joining Cardiome, Mr. Rieder was Vice-President at MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp., and has served as a director for nine public and private technology companies. Mr. Rieder has also acted as Chief Operating Officer for DBA Telecom Inc., and CEO for Synapse Technologies Inc. Mr. Rieder received his MBA from the University of Western Ontario.
Janzen, Douglas Mr. Douglas G. Janzen has been appointed as President and Chief Executive Officer of Cardiome Pharma Corp. effective August 4, 2009. He was President, Chief Business Officer of the company. He also serves as Director of Cardiome Pharma Corp. Mr. Janzen manages all of Cardiome’s business activities, including capital markets, commercial development, partnering, licensing and other strategic transactions. Mr. Janzen joined Cardiome in 2003 as Chief Financial Officer. He has been instrumental to the advancement of Cardiome’s corporate development and the strengthening of its financial position. Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank.
Sikorsky, Curtis Curtis Sikorsky is Chief Financial Officer of Cardiome Pharma Corp., with responsibility for overseeing the company’s financial operations. He joined Cardiome in June 2006, bringing over ten years of public and private company experience as well as three years of direct audit and tax experience. Prior to joining Cardiome, he was Vice President of Finance at NxtPhase T&D Corporation, a private Vancouver-based energy technology company. He has also held senior financial roles including Vice President and Corporate Controller with 360networks inc. and Corporate Controller with WIC Western International Communications. Mr. Sikorsky began his career with KPMG performing audit, tax and accounting work for clients. He is a Chartered Accountant and holds a Bachelor of Commerce Degree from the University of Saskatchewan.
Lalji, Karim Karim Lalji is Senior Vice President, Commercial Affairs of Cardiome Pharma Corp. Bringing over 16 years of experience in pharmaceutical business strategy, product commercialization and marketing to Cardiome, Mr. Lalji was previously Vice President of Business Strategy and New Product Commercialization at Sepracor, Inc. At Sepracor, Inc., he was responsible for the commercial success of their pipeline of drug candidates, including identifying which products to take into development and ensuring that the development program and marketing strategy resulted in successful product launches. One of the key achievements for Mr. Lalji at Sepracor, Inc. was his leadership in the development and launch of Lunesta (eszopiclone) for the treatment of insomnia. Mr. Lalji’s earlier experience includes ten years with Merck & Company, where he led several successful product launches. Mr. Lalji also has cardiovascular experience from Merck & Company as the Director of Business Strategy for the cholesterol reducers and hypertension/heart failure franchises. Mr. Lalji is currently a member of the Board of Overseers at the Beth Israel Deaconess Hospital Medical Center in Boston, Massachusetts, an academic teaching hospital for Harvard Medical School. Mr. Lalji holds a Bachelors Degree in Business Administration from Simon Fraser University and a Science Masters in Health Policy and Management from Harvard University. He was awarded the Wilinsky Prize for Academic Excellence while at Harvard.
Grant, Sheila Sheila M. Grant is Vice President of Product Development for vernakalant of Cardiome Pharma Corp. She is responsible for the overall management of the vernakalant (iv) and vernakalant (oral) programs. She has overseen development of vernakalant from its initial toxicology studies as a clinical candidate in 1999, through to its current stage of development. Ms. Grant’s past roles at Cardiome have included Vice President, Commercial Affairs and Director of Business & Clinical Development. Prior to joining Cardiome, Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. Ms. Grant also worked in research and development, production, and quality assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono Diagnostics U.K. respectively. Ms. Grant holds a B.Sc. (Hons) degree from Essex University, U.K. and an MBA degree from Simon Fraser University.
Boivin, Taryn Dr. Taryn Boivin is Vice President of Pharmaceutical Sciences & Manufacturing. Dr. Boivin has over 18 years of Pharmaceutical Development experience in both multi-national and start-up pharmaceutical operations. Early in her career, Dr. Boivin was a member of the Glaxo Canada Pharmaceutical Development organization, or GSK, and was instrumental in growing the operation into a world-class research and development facility. While at GSK, Dr. Boivin’s work involved progression of development programmes in a wide range of areas including treatments for oncology related emesis, HIV, malaria, ulcers, and asthma. Following 11 years with GSK, Dr. Boivin assumed the responsibility of Business Manager, Life Sciences at Agilent Technologies Inc. (formerly Hewlett Packard) where she led a sales, service, and marketing operation in Central and Western Canada. More recently, she was Principal of Level 10 BioSciences Ltd., a privately held consulting company on the West Coast, and just prior to joining Cardiome, was Vice President, Pharmaceutical Development at Oncogenex Technologies Inc. in Vancouver. Her experience spans Analytical Development, Pharmaceutical Development, CMC Regulatory Affairs, Quality Assurance, Manufacturing and Business Development. Dr. Boivin holds a Ph.D. in Chemistry from the University of Alberta and a BSc. from Simon Fraser University.
McAfee, Donald Dr. Donald A. McAfee is Chief Scientific Officer of Cardiome Pharma Corp. He joined Cardiome in October 2004 as Vice President of New Product Development. He has been a scientist and manager in academia and industry for more than 40 years. As Founder, CEO, and CTO of Aderis Pharmaceuticals, Inc. (formerly Discovery Therapeutics, Inc.), Dr. McAfee led the introduction of a number of clinical candidates including a therapeutic patch for Parkinson’s disease now marketed, and adenosine receptor based cardiovascular therapeutics and diagnostics still in development.
Glickman, Richard Richard M. Glickman is Lead Independent Director of Cardiome Pharma Corp. Dr. Glickman was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals, or Aspreva. Prior to establishing Aspreva, Dr. Glickman was the cofounder and Chief Executive Officer of StressGen Biotechnologies Corporation. Since 2000, Dr. Glickman has served as the Chairman of the Board of Vigil Health Solutions Inc., a healthcare services company. Dr. Glickman was also the founder and a director of Ontario Molecular Diagnostics, a diagnostic facility that evolved into one of the largest molecular diagnostic laboratories in Canada. He co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C. (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Disease Network and a member of the federal government’s National Biotechnology Advisory Committee. Dr. Glickman currently serves as a member of the British Columbia Innovation Council and a Director for the Vancouver Aquarium. Dr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group and has received both Canada’s and British Columbia’s Top 40 under 40 Award for Entrepreneurs and has been the recipient of 2006 BC Biotech Leadership Award.
Shlevin, Harold Harold H. Shlevin, Ph.D., is Director of Cardiome Pharma Corp. Dr. Shlevin is Head of Operations for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water-soluble biotherapeutics and small drugs through the skin. He joined Altea in October 2008, and is responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. Prior to this, Mr. Shlevin was the President and CEO of Tikvah Therapeutics, Inc., a pharmaceutical enterprise focused on late-stage development of neuroscience therapeutics. He was previously the Global Senior Vice President, and a member of the boards of Solvay Pharmaceutical, SA and Solvay Pharmaceuticals Inc., CEO of Solvay Pharmaceuticals, Inc. He was also Chairman of the Board of Solvay’s subsidiary Unimed Pharmaceuticals, Inc., and a member of the board of Solvay Draka, a specialty plastic company with medical device products. Dr. Shlevin has over twenty-five years of diverse healthcare business-related and global management experience. His direct skills and experience span functions from R&D through commercial operations, including many international roles. His past industry experience includes leadership roles at G.D. Searle and Co., Revlon Health Care Group, Ciba-Geigy Corporation, Bausch and Lomb Pharmaceuticals, and he was a founder of Ciba Vision Ophthalmics. Dr. Shlevin’s experience related to his responsibilities as an audit committee member include his tenure as CEO of Solvay and as Senior Vice President where he was regularly involved in assessments and analysis of financial statements and projections and acquisitions of companies and of products. Dr. Shlevin has also taken courses in financial strategies.
Clegg, Jackie Jackie M. Clegg is Director of Cardiome Pharma Corp. Ms. Jackie Clegg currently serves as a Managing Partner of Clegg International Consultants, LLC. Ms. Clegg is a member of the board of directors of Javelin Pharmaceuticals, Inc., the Chicago Mercantile Exchange and Brookdale Senior Living. She is also on the board of Blockbuster Inc., where she serves as the Chair of the Corporate Governance Committee. She has served as the chair of special committees for divestiture, mergers and acquisitions. Previously, Ms. Clegg served in the U.S. Government as Vice Chair of the Export-Import Bank of the U.S. (Ex-ImBank). Prior to joining Ex-ImBank, she served as a staff member on the U.S. Senate Committee on Banking International Finance Subcommittee and as an associate staff member to the U.S. Senate Committee on Appropriations.
Roberts, Peter Peter W. Roberts is Director of Cardiome Pharma Corp. Mr. Roberts retired as Chief Financial Officer and Corporate Secretary of Sierra Wireless, Inc. (NASDAQ: SWIR / TSX: SW) in March 2004. He served in this role from January 1999 until retirement, and was responsible for taking the company public on the Toronto Stock Exchange in May 1999 and a follow-on financing on NASDAQ in May 2000. Prior to joining Sierra Wireless, Inc., Mr. Roberts held senior financial roles over a fifteen-year period with Service Corporation IJK plc, The Loewen Group Inc., The Overwaitea and Save-On Foods Chain and Sydney Development Corporation. Mr. Roberts is a graduate of Touche Ross, and practiced a decade in public accounting. He holds professional accounting designations in Canada, the United States, and the United Kingdom. In June 2007, Mr. Roberts completed his term as President of the Institute of Chartered Accountants of British Columbia. Mr. Roberts is vice chair of the Risk Management and Governance Board of the Canadian Institute of Chartered Accountants, and is a graduate of the Institute of Corporate Directors.
Hunter, William William L. Hunter is Director of Cardiome Pharma Corp. Dr. Hunter is one of Angiotech Pharmaceuticals Inc.’s (“Angiotech”) co-founders and currently serves as President and CEO of Angiotech. He has led Angiotech through significant corporate milestones from its initial rounds of private and public financings, to product commercialization and profitability. The company’s initial lead product, the TAXUS® drug-eluting coronary stent that is co-developed and sold by Boston Scientific Corporation, is implanted in over four million patients worldwide. Angiotech is a global leader in the field of drug-device combination products and manufacturer of over 5,000 specialty, single-use medical devices and medical device components targeting various surgical and interventional medical markets. Active in a variety of business and scientific organizations, Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals Ltd. Dr. Hunter has been honoured with many awards including the 2006 Principal Award for Innovation from the Manning Foundation, the 2005 BC Innovation Council’s Cecil Green Award for Science and Technology Entrepreneurship and the co-recipient of 2006 NSERC Synergy Awards for Innovation along with Dr. Helen Burt, recognizing the collaboration between the University of British Columbia and Angiotech. Dr. Hunter received his BSc from McGill University, and MSc and MD from the University of British Columbia.

Basic Compensation

Name Fiscal Year Total
Rieder, Robert 610,635
Janzen, Douglas 489,998
Sikorsky, Curtis 297,200
Lalji, Karim --
Grant, Sheila --
Boivin, Taryn --
McAfee, Donald 316,330
Glickman, Richard --
Shlevin, Harold --
Clegg, Jackie 597,125
Roberts, Peter --
Hunter, William --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Rieder, Robert 704,398 3,529,488
Janzen, Douglas 777,737 2,409,299
Sikorsky, Curtis 207,121 0
Lalji, Karim 0 0
Grant, Sheila 0 0
Boivin, Taryn 0 0
McAfee, Donald 280,339 660,620
Glickman, Richard 0 0
Shlevin, Harold 0 0
Clegg, Jackie 0 0
Roberts, Peter 0 0
Hunter, William 0 0

Insider Trading

Name Shares Traded Price
ADAGE CAPITAL PARTNERS GP L L C 1,000,000 $3.92
» Full list on Insider Trading
view people for: